Chugai Pharmaceutical Co., Ltd.
4519
주식 순위
#356
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
주가
$41.71
마지막 동기화: 2026-10-16
시가총액
$68.64B
변동 (1일)
2.01%
변동 (1년)
-14.16%
국가
JP
거래 Chugai Pharmaceutical Co., Ltd. (4519)
카테고리
Healthcare
의 시가총액 Chugai Pharmaceutical Co., Ltd.(4519)
시가총액: $68.64B
October 2026 기준으로 Chugai Pharmaceutical Co., Ltd.의 시가총액은 $68.64B입니다. 이는 당사 데이터에 따르면 Chugai Pharmaceutical Co., Ltd.이 세계에서 356th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2000부터 2026까지 Chugai Pharmaceutical Co., Ltd.의 시가총액 기록
